fbpx

2:50 – 3:05

Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptorpositive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

GS1-02

Social Share

× How can I help you?